AstraZeneca PLC (AZN) 10-Year Financial Performance & Capital Metrics

AZN •

HealthcareLarge PharmaLarge diversified branded pharma

AboutAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.Show more

Revenue $58.74B +8.6%
EBITDA $19.48B +29.3%
Net Income $10.26B +45.8%
EPS (Diluted) 3.27 +189.4%
Gross Margin 81.9% +1.0%
EBITDA Margin 33.16% +19.0%
Operating Margin 23.4% +26.5%
Net Margin 17.46% +34.2%
ROE 22.89% +30.2%
ROIC 14.92% +26.7%
Debt/Equity 0.61 -17.3%
Interest Coverage 8.11 +36.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 26.3%
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 20.0% free cash flow margin
✓Momentum leader: RS Rating 81 (top 19%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.2%

✗Weaknesses

✗Expensive at 13.4x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.05%

5Y17.15%

3Y9.82%

TTM8.63%

Profit (Net Income) CAGR

10Y13.76%

5Y26.26%

3Y46.11%

TTM45.34%

EPS CAGR

10Y11.31%

5Y21.8%

3Y45.57%

TTM45.13%

ROCE

10Y Avg9.3%

5Y Avg9.81%

3Y Avg14.16%

Latest17.22%

Peer Comparison

Large diversified branded pharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LLYEli Lilly and Company	941.74B	1052.20	89.85	32%	30.99%	77.2%	0.04%	2.36
AZNAstraZeneca PLC	323.16B	208.45	63.75	8.63%	17.41%	20.99%	3.64%	0.61
JNJJohnson & Johnson	598.69B	248.43	42.91	4.3%	27.26%	31.69%	3.31%	0.51
CELG-RIBristol-Myers Squibb Company Ce		0.10	-0.02	7.32%	12.57%	32.47%		3.12
BMYBristol-Myers Squibb Company	127.01B	62.37	-14.14	7.32%	12.57%	32.47%	10.98%	3.12

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	23B	22.46B	22.09B	24.38B	26.62B	37.42B	44.35B	45.81B	54.07B	58.74B
Revenue Growth %	-6.9%	-2.33%	-1.67%	10.38%	9.16%	40.58%	18.53%	3.29%	18.04%	8.63%
Cost of Goods Sold+	4.13B	4.32B	4.94B	4.92B	5.3B	12.44B	12.39B	8.27B	10.21B	10.63B
COGS % of Revenue	17.94%	19.22%	22.35%	20.18%	19.91%	33.24%	27.94%	18.05%	18.88%	18.1%
Gross Profit+	18.88B	18.15B	17.15B	19.46B	21.32B	24.98B	31.96B	37.54B	43.87B	48.11B
Gross Margin %	82.06%	80.78%	77.66%	79.82%	80.09%	66.76%	72.06%	81.95%	81.12%	81.9%
Gross Profit Growth %	-5.91%	-3.86%	-5.47%	13.46%	9.53%	17.18%	27.94%	17.47%	16.84%	9.67%
Operating Expenses+	13.97B	14.47B	13.77B	16.54B	16.16B	23.92B	28.2B	29.35B	33.86B	34.36B
OpEx % of Revenue	60.75%	64.41%	62.32%	67.83%	60.7%	63.94%	63.59%	64.07%	62.62%	58.5%
Selling, General & Admin	9.74B	10.54B	10.98B	11.98B	11.9B	15.59B	17.98B	18.22B	20.22B	20.51B
SG&A % of Revenue	42.34%	46.93%	49.71%	49.15%	44.69%	41.67%	40.55%	39.78%	37.4%	34.92%
Research & Development	5.89B	5.76B	5.93B	6.06B	5.99B	9.74B	9.76B	10.94B	13.58B	14.23B
R&D % of Revenue	25.61%	25.63%	26.85%	24.85%	22.51%	26.02%	22.01%	23.87%	25.12%	24.23%
Other Operating Expenses	-1.66B	-1.83B	-3.15B	-1.5B	-1.73B	-1.4B	457M	193M	56M	-381M
Operating Income+	4.9B	3.68B	3.39B	2.92B	5.16B	1.06B	3.76B	8.19B	10B	13.74B
Operating Margin %	21.31%	16.37%	15.33%	11.99%	19.39%	2.82%	8.47%	17.88%	18.5%	23.4%
Operating Income Growth %	19.15%	-24.99%	-7.89%	-13.67%	76.54%	-79.54%	255.78%	118.07%	22.09%	37.39%
EBITDA+	7.26B	6.71B	7.14B	6.69B	8.06B	5.16B	9.01B	13.13B	15.07B	19.48B
EBITDA Margin %	31.56%	29.88%	32.32%	27.42%	30.27%	13.79%	20.32%	28.65%	27.87%	33.16%
EBITDA Growth %	4.21%	-7.52%	6.36%	-6.36%	20.52%	-35.99%	74.7%	45.68%	14.79%	29.25%
D&A (Non-Cash Add-back)	2.36B	3.04B	3.75B	3.76B	2.9B	4.1B	5.25B	4.93B	5.07B	5.73B
EBIT	4.92B	3.59B	3.36B	2.95B	5.19B	1.01B	3.83B	8.49B	10.37B	14.1B
Net Interest Income+	-1.31B	-1.25B	-1.23B	-1.24B	-1.19B	-1.23B	-1.25B	-1.29B	-1.34B	-1.33B
Interest Income	59M	109M	138M	165M	83M	43M	81M	301M	345M	360M
Interest Expense	1.37B	1.36B	1.37B	1.4B	1.27B	1.28B	1.33B	1.59B	1.68B	1.69B
Other Income/Expense	-1.35B	-1.45B	-1.39B	-1.38B	-1.25B	-1.32B	-1.26B	-1.29B	-1.31B	-1.34B
Pretax Income+	3.55B	2.23B	1.99B	1.55B	3.92B	-265M	2.5B	6.9B	8.69B	12.4B
Pretax Margin %	15.44%	9.91%	9.02%	6.35%	14.71%	-0.71%	5.64%	15.06%	16.07%	21.11%
Income Tax+	146M	-641M	-57M	321M	772M	-380M	-792M	938M	1.65B	2.17B
Effective Tax Rate %	98.51%	134.76%	108.13%	86.24%	81.61%	-42.26%	131.47%	86.32%	80.95%	82.69%
Net Income+	3.5B	3B	2.15B	1.33B	3.2B	112M	3.29B	5.96B	7.04B	10.26B
Net Margin %	15.21%	13.36%	9.76%	5.47%	12.01%	0.3%	7.41%	13%	13.01%	17.46%
Net Income Growth %	23.86%	-14.23%	-28.19%	-38.05%	139.4%	-96.5%	2835.71%	81.11%	18.14%	45.77%
Net Income (Continuing)	3.41B	2.87B	2.05B	1.23B	3.14B	115M	3.29B	5.96B	7.04B	10.23B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	1.81B	1.68B	1.58B	1.47B	16M	19M	21M	23M	85M	52M
EPS (Diluted)+	1.38	1.19	0.85	0.52	1.22	0.04	1.06	1.91	1.13	3.27
EPS Growth %	23.21%	-13.77%	-28.57%	-38.82%	134.62%	-96.72%	2550%	80.19%	-40.84%	189.38%
EPS (Basic)	1.39	1.19	0.85	0.52	1.22	0.04	1.06	1.91	1.14	3.30
Diluted Shares Outstanding	2.53B	2.53B	2.53B	2.6B	2.63B	2.85B	3.12B	3.12B	3.13B	3.12B
Basic Shares Outstanding	2.53B	2.53B	2.53B	2.6B	2.62B	2.84B	3.1B	3.12B	3.1B	3.1B
Dividend Payout Ratio	101.77%	117.26%	161.67%	269.06%	111.76%	3442.86%	132.73%	75.25%	65.8%	49.55%

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	13.26B	13.15B	15.59B	15.56B	19.54B	26.24B	22.59B	25.05B	25.83B	28.72B
Cash & Short-Term Investments	5.9B	4.55B	5.68B	6.22B	7.99B	6.4B	6.24B	5.86B	5.53B	5.74B
Cash Only	5.02B	3.32B	4.83B	5.37B	7.83B	6.33B	6.17B	5.84B	5.49B	5.71B
Short-Term Investments	884M	1.23B	849M	849M	160M	69M	77M	20M	37M	30M
Accounts Receivable	2.58B	2.8B	3B	4.9B	5.65B	8.13B	9.19B	8.41B	11.23B	15.18B
Days Sales Outstanding	40.99	45.53	49.49	73.29	77.49	79.33	75.65	66.98	75.84	94.31
Inventory	2.33B	3.04B	2.89B	3.19B	4.02B	8.98B	4.7B	5.42B	5.29B	6.56B
Days Inventory Outstanding	206.47	256.55	213.71	236.83	277.18	263.63	138.42	239.45	189.1	225.08
Other Current Assets	2.31B	1.68B	3.08B	392M	142M	1.22B	1.13B	3.75B	2.04B	1.25B
Total Non-Current Assets+	49.26B	50.2B	45.06B	45.81B	47.19B	79.12B	73.89B	76.06B	78.21B	85.35B
Property, Plant & Equipment	6.85B	7.62B	7.42B	8.34B	8.92B	10.17B	9.45B	10.5B	11.65B	14.7B
Fixed Asset Turnover	3.36x	2.95x	2.98x	2.93x	2.98x	3.68x	4.69x	4.36x	4.64x	4.00x
Goodwill	11.66B	11.82B	11.71B	11.67B	11.85B	20B	19.82B	20.05B	21.02B	21.24B
Intangible Assets	27.59B	26.19B	21.96B	20.83B	20.95B	42.39B	39.31B	38.09B	37.18B	37.85B
Long-Term Investments	-58M	-194M	113M	0	0	0	0	1.78B	0	2.52B
Other Non-Current Assets	2.13B	2.58B	1.48B	2.26B	2.04B	2.23B	2.05B	5.65B	3.01B	9.04B
Total Assets+	62.53B	63.35B	60.65B	61.38B	66.73B	105.36B	96.48B	101.12B	104.03B	114.07B
Asset Turnover	0.37x	0.35x	0.36x	0.40x	0.40x	0.36x	0.46x	0.45x	0.52x	0.51x
Asset Growth %	4%	1.32%	-4.27%	1.2%	8.72%	57.9%	-8.43%	4.81%	2.88%	9.65%
Total Current Liabilities+	15.26B	16.38B	16.29B	18.12B	20.31B	22.59B	26.29B	30.54B	27.87B	30.62B
Accounts Payable	1.68B	2.29B	1.72B	1.77B	2.35B	2.82B	2.55B	3.27B	3.64B	25.28B
Days Payables Outstanding	148.62	193.15	127.19	131.58	161.87	82.88	75.11	144.23	130.17	867.79
Short-Term Debt	2.24B	2.27B	1.78B	1.82B	2.19B	1.57B	5.22B	5.13B	2.16B	3.19B
Deferred Revenue (Current)	-5.88B	-6.44B	1.37B	0	0	0	0	0	0	0
Other Current Liabilities	4B	4.21B	3.73B	9.96B	12.27B	14.94B	15B	6.13B	17.31B	1.77B
Current Ratio	0.87x	0.80x	0.96x	0.86x	0.96x	1.16x	0.86x	0.82x	0.93x	0.94x
Quick Ratio	0.72x	0.62x	0.78x	0.68x	0.76x	0.76x	0.68x	0.64x	0.74x	0.72x
Cash Conversion Cycle	98.84	108.92	136	178.54	192.8	260.08	138.95	162.21	134.77	-548.4
Total Non-Current Liabilities+	30.6B	30.33B	30.32B	28.66B	30.78B	43.48B	33.13B	31.41B	35.3B	34.74B
Long-Term Debt	16.51B	17.39B	19.2B	15.73B	17.5B	28.13B	22.96B	22.36B	26.51B	24.71B
Capital Lease Obligations	6M	0	0	487M	489M	754M	725M	857M	1.11B	1.42B
Deferred Tax Liabilities	3.96B	4B	3.29B	2.49B	2.92B	6.21B	2.94B	31M	3.31B	3.51B
Other Non-Current Liabilities	14.08B	12.94B	11.11B	9.91B	9.83B	8.36B	6.48B	8.15B	4.37B	3.69B
Total Liabilities	45.86B	46.71B	46.61B	46.78B	51.09B	66.08B	59.42B	61.95B	63.16B	65.36B
Total Debt+	16.81B	17.81B	19.11B	18.23B	20.38B	30.69B	29.14B	28.62B	30.11B	29.7B
Net Debt	11.79B	14.48B	14.28B	12.86B	12.55B	24.36B	22.98B	22.78B	24.63B	23.99B
Debt / Equity	1.01x	1.07x	1.36x	1.25x	1.30x	0.78x	0.79x	0.73x	0.74x	0.61x
Debt / EBITDA	2.32x	2.65x	2.68x	2.73x	2.53x	5.95x	3.23x	2.18x	2.00x	1.53x
Net Debt / EBITDA	1.62x	2.16x	2.00x	1.92x	1.56x	4.72x	2.55x	1.74x	1.63x	1.23x
Interest Coverage	3.59x	2.70x	2.48x	2.09x	4.06x	0.83x	2.82x	5.16x	5.95x	8.11x
Total Equity+	16.67B	16.64B	14.04B	14.6B	15.64B	39.29B	37.06B	39.17B	40.87B	48.72B
Equity Growth %	-9.94%	-0.16%	-15.61%	3.93%	7.14%	151.23%	-5.67%	5.69%	4.35%	19.2%
Book Value per Share	6.58	6.57	5.54	5.61	5.96	13.77	11.88	12.54	13.07	15.60
Total Shareholders' Equity	14.85B	14.96B	12.47B	13.13B	15.62B	39.27B	37.04B	39.14B	40.79B	48.67B
Common Stock	316M	317M	317M	328M	328M	387M	387M	388M	388M	388M
Retained Earnings	8.14B	8.22B	5.68B	2.81B	5.3B	1.71B	-574M	4.52B	3.16B	10.97B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	99M	1.01B	34M	0	0	0	0	0	0	2.04B
Minority Interest	1.81B	1.68B	1.58B	1.47B	16M	19M	21M	23M	85M	52M

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	4.14B	3.58B	2.62B	2.97B	4.8B	5.96B	9.81B	10.35B	11.86B	15.19B
Operating CF Margin %	18.02%	15.93%	11.85%	12.18%	18.03%	15.94%	22.11%	22.58%	21.94%	25.86%
Operating CF Growth %	24.7%	-13.68%	-26.83%	13.41%	61.64%	24.26%	64.48%	5.48%	14.65%	28.08%
Net Income	3.55B	2.23B	1.99B	1.55B	3.92B	-265M	2.5B	6.9B	8.69B	10.22B
Depreciation & Amortization	2.36B	3.04B	3.75B	3.76B	3.15B	6.53B	5.48B	4.93B	5.07B	5.73B
Stock-Based Compensation	0	0	0	259M	277M	615M	619M	579M	0	0
Deferred Taxes	0	0	0	-259M	-277M	-615M	-619M	0	0	0
Other Non-Cash Items	-2.69B	-1.64B	-2.49B	-2B	-2.63B	-2.32B	-1.93B	-2.37B	-1B	395.79M
Working Capital Changes	926M	-50M	-639M	-346M	361M	2.02B	3.76B	300M	-893M	-1.16B
Change in Receivables	1.61B	83M	-523M	-898M	-739M	-961M	-1.35B	-1.43B	-1.62B	0
Change in Inventory	-343M	-548M	-13M	-316M	-621M	1.58B	3.94B	-669M	-131M	0
Change in Payables	0	0	0	898M	739M	961M	1.35B	1.43B	0	0
Cash from Investing+	-3.97B	-2.33B	963M	-657M	-285M	-11.06B	-2.96B	-4.06B	-7.98B	-7.25B
Capital Expenditures	-2.31B	-1.62B	-1.37B	-2.46B	-2.61B	-2.2B	-2.57B	-1.36B	-1.92B	-2.81B
CapEx % of Revenue	10.06%	7.21%	6.21%	10.09%	9.79%	5.88%	5.8%	2.97%	3.56%	4.78%
Acquisitions	-2.9B	-1.96B	-536M	-783M	-830M	-9.43B	-1.06B	-1.18B	-3.93B	-1.23B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.64B	1.62B	2.54B	2.39B	1.14B	654M	789M	-1.52B	-2.14B	-3.21B
Cash from Financing+	-1.32B	-2.94B	-2.04B	-1.76B	-2.2B	3.65B	-6.82B	-6.57B	-4B	-7.71B
Debt Issued (Net)	2.48B	224M	1.47B	-1.19B	1.65B	7.89B	-1.2B	-965M	1.81B	-2.39B
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	-1000K	-1000K
Dividends Paid	-3.56B	-3.52B	-3.48B	-3.59B	-3.57B	-3.86B	-4.36B	-4.48B	-4.63B	-5.08B
Share Repurchases	0	0	0	0	0	0	0	0	0	-719.66M
Other Financing	-285M	316M	-33M	3.01B	-308M	-418M	-1.29B	-1.15B	-1.13B	434.54M
Net Change in Cash	-1.13B	-1.75B	1.5B	552M	2.32B	-1.51B	-55M	-346M	-208M	237.82M
Free Cash Flow+	1.83B	1.96B	1.25B	509M	2.19B	3.76B	7.24B	6.57B	7.28B	11.77B
FCF Margin %	7.96%	8.72%	5.65%	2.09%	8.24%	10.06%	16.32%	14.34%	13.45%	20.03%
FCF Growth %	241.6%	6.94%	-36.31%	-59.18%	330.84%	71.59%	92.32%	-9.26%	10.78%	61.72%
FCF per Share	0.72	0.77	0.49	0.20	0.84	1.32	2.32	2.10	2.33	3.77
FCF Conversion (FCF/Net Income)	1.18x	1.19x	1.21x	2.22x	1.50x	53.24x	2.98x	1.74x	1.69x	1.48x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	19.89%	18.02%	14.05%	9.32%	21.14%	0.41%	8.61%	15.63%	17.58%	22.89%
Return on Invested Capital (ROIC)	13.18%	9.26%	8.55%	7.86%	13.92%	1.72%	4.56%	10.07%	11.77%	14.92%
Gross Margin	82.06%	80.78%	77.66%	79.82%	80.09%	66.76%	72.06%	81.95%	81.12%	81.9%
Net Margin	15.21%	13.36%	9.76%	5.47%	12.01%	0.3%	7.41%	13%	13.01%	17.46%
Debt / Equity	1.01x	1.07x	1.36x	1.25x	1.30x	0.78x	0.79x	0.73x	0.74x	0.61x
Interest Coverage	3.59x	2.70x	2.48x	2.09x	4.06x	0.83x	2.82x	5.16x	5.95x	8.11x
FCF Conversion	1.18x	1.19x	1.21x	2.22x	1.50x	53.24x	2.98x	1.74x	1.69x	1.48x
Revenue Growth	-6.9%	-2.33%	-1.67%	10.38%	9.16%	40.58%	18.53%	3.29%	18.04%	8.63%

US Stock Screener

...

AstraZeneca PLC (AZN) 10-Year Financial Performance & Capital Metrics

AZN •

HealthcareLarge PharmaLarge diversified branded pharma

Revenue $58.74B +8.6%
EBITDA $19.48B +29.3%
Net Income $10.26B +45.8%
EPS (Diluted) 3.27 +189.4%
Gross Margin 81.9% +1.0%
EBITDA Margin 33.16% +19.0%
Operating Margin 23.4% +26.5%
Net Margin 17.46% +34.2%
ROE 22.89% +30.2%
ROIC 14.92% +26.7%
Debt/Equity 0.61 -17.3%
Interest Coverage 8.11 +36.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 26.3%
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 20.0% free cash flow margin
✓Momentum leader: RS Rating 81 (top 19%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.2%

✗Weaknesses

✗Expensive at 13.4x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.05%

5Y17.15%

3Y9.82%

TTM8.63%

Profit (Net Income) CAGR

10Y13.76%

5Y26.26%

3Y46.11%

TTM45.34%

EPS CAGR

10Y11.31%

5Y21.8%

3Y45.57%

TTM45.13%

ROCE

10Y Avg9.3%

5Y Avg9.81%

3Y Avg14.16%

Latest17.22%

Peer Comparison

Large diversified branded pharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LLYEli Lilly and Company	941.74B	1052.20	89.85	32%	30.99%	77.2%	0.04%	2.36
AZNAstraZeneca PLC	323.16B	208.45	63.75	8.63%	17.41%	20.99%	3.64%	0.61
JNJJohnson & Johnson	598.69B	248.43	42.91	4.3%	27.26%	31.69%	3.31%	0.51
CELG-RIBristol-Myers Squibb Company Ce		0.10	-0.02	7.32%	12.57%	32.47%		3.12
BMYBristol-Myers Squibb Company	127.01B	62.37	-14.14	7.32%	12.57%	32.47%	10.98%	3.12

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	23B	22.46B	22.09B	24.38B	26.62B	37.42B	44.35B	45.81B	54.07B	58.74B
Revenue Growth %	-6.9%	-2.33%	-1.67%	10.38%	9.16%	40.58%	18.53%	3.29%	18.04%	8.63%
Cost of Goods Sold+	4.13B	4.32B	4.94B	4.92B	5.3B	12.44B	12.39B	8.27B	10.21B	10.63B
COGS % of Revenue	17.94%	19.22%	22.35%	20.18%	19.91%	33.24%	27.94%	18.05%	18.88%	18.1%
Gross Profit+	18.88B	18.15B	17.15B	19.46B	21.32B	24.98B	31.96B	37.54B	43.87B	48.11B
Gross Margin %	82.06%	80.78%	77.66%	79.82%	80.09%	66.76%	72.06%	81.95%	81.12%	81.9%
Gross Profit Growth %	-5.91%	-3.86%	-5.47%	13.46%	9.53%	17.18%	27.94%	17.47%	16.84%	9.67%
Operating Expenses+	13.97B	14.47B	13.77B	16.54B	16.16B	23.92B	28.2B	29.35B	33.86B	34.36B
OpEx % of Revenue	60.75%	64.41%	62.32%	67.83%	60.7%	63.94%	63.59%	64.07%	62.62%	58.5%
Selling, General & Admin	9.74B	10.54B	10.98B	11.98B	11.9B	15.59B	17.98B	18.22B	20.22B	20.51B
SG&A % of Revenue	42.34%	46.93%	49.71%	49.15%	44.69%	41.67%	40.55%	39.78%	37.4%	34.92%
Research & Development	5.89B	5.76B	5.93B	6.06B	5.99B	9.74B	9.76B	10.94B	13.58B	14.23B
R&D % of Revenue	25.61%	25.63%	26.85%	24.85%	22.51%	26.02%	22.01%	23.87%	25.12%	24.23%
Other Operating Expenses	-1.66B	-1.83B	-3.15B	-1.5B	-1.73B	-1.4B	457M	193M	56M	-381M
Operating Income+	4.9B	3.68B	3.39B	2.92B	5.16B	1.06B	3.76B	8.19B	10B	13.74B
Operating Margin %	21.31%	16.37%	15.33%	11.99%	19.39%	2.82%	8.47%	17.88%	18.5%	23.4%
Operating Income Growth %	19.15%	-24.99%	-7.89%	-13.67%	76.54%	-79.54%	255.78%	118.07%	22.09%	37.39%
EBITDA+	7.26B	6.71B	7.14B	6.69B	8.06B	5.16B	9.01B	13.13B	15.07B	19.48B
EBITDA Margin %	31.56%	29.88%	32.32%	27.42%	30.27%	13.79%	20.32%	28.65%	27.87%	33.16%
EBITDA Growth %	4.21%	-7.52%	6.36%	-6.36%	20.52%	-35.99%	74.7%	45.68%	14.79%	29.25%
D&A (Non-Cash Add-back)	2.36B	3.04B	3.75B	3.76B	2.9B	4.1B	5.25B	4.93B	5.07B	5.73B
EBIT	4.92B	3.59B	3.36B	2.95B	5.19B	1.01B	3.83B	8.49B	10.37B	14.1B
Net Interest Income+	-1.31B	-1.25B	-1.23B	-1.24B	-1.19B	-1.23B	-1.25B	-1.29B	-1.34B	-1.33B
Interest Income	59M	109M	138M	165M	83M	43M	81M	301M	345M	360M
Interest Expense	1.37B	1.36B	1.37B	1.4B	1.27B	1.28B	1.33B	1.59B	1.68B	1.69B
Other Income/Expense	-1.35B	-1.45B	-1.39B	-1.38B	-1.25B	-1.32B	-1.26B	-1.29B	-1.31B	-1.34B
Pretax Income+	3.55B	2.23B	1.99B	1.55B	3.92B	-265M	2.5B	6.9B	8.69B	12.4B
Pretax Margin %	15.44%	9.91%	9.02%	6.35%	14.71%	-0.71%	5.64%	15.06%	16.07%	21.11%
Income Tax+	146M	-641M	-57M	321M	772M	-380M	-792M	938M	1.65B	2.17B
Effective Tax Rate %	98.51%	134.76%	108.13%	86.24%	81.61%	-42.26%	131.47%	86.32%	80.95%	82.69%
Net Income+	3.5B	3B	2.15B	1.33B	3.2B	112M	3.29B	5.96B	7.04B	10.26B
Net Margin %	15.21%	13.36%	9.76%	5.47%	12.01%	0.3%	7.41%	13%	13.01%	17.46%
Net Income Growth %	23.86%	-14.23%	-28.19%	-38.05%	139.4%	-96.5%	2835.71%	81.11%	18.14%	45.77%
Net Income (Continuing)	3.41B	2.87B	2.05B	1.23B	3.14B	115M	3.29B	5.96B	7.04B	10.23B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	1.81B	1.68B	1.58B	1.47B	16M	19M	21M	23M	85M	52M
EPS (Diluted)+	1.38	1.19	0.85	0.52	1.22	0.04	1.06	1.91	1.13	3.27
EPS Growth %	23.21%	-13.77%	-28.57%	-38.82%	134.62%	-96.72%	2550%	80.19%	-40.84%	189.38%
EPS (Basic)	1.39	1.19	0.85	0.52	1.22	0.04	1.06	1.91	1.14	3.30
Diluted Shares Outstanding	2.53B	2.53B	2.53B	2.6B	2.63B	2.85B	3.12B	3.12B	3.13B	3.12B
Basic Shares Outstanding	2.53B	2.53B	2.53B	2.6B	2.62B	2.84B	3.1B	3.12B	3.1B	3.1B
Dividend Payout Ratio	101.77%	117.26%	161.67%	269.06%	111.76%	3442.86%	132.73%	75.25%	65.8%	49.55%

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	13.26B	13.15B	15.59B	15.56B	19.54B	26.24B	22.59B	25.05B	25.83B	28.72B
Cash & Short-Term Investments	5.9B	4.55B	5.68B	6.22B	7.99B	6.4B	6.24B	5.86B	5.53B	5.74B
Cash Only	5.02B	3.32B	4.83B	5.37B	7.83B	6.33B	6.17B	5.84B	5.49B	5.71B
Short-Term Investments	884M	1.23B	849M	849M	160M	69M	77M	20M	37M	30M
Accounts Receivable	2.58B	2.8B	3B	4.9B	5.65B	8.13B	9.19B	8.41B	11.23B	15.18B
Days Sales Outstanding	40.99	45.53	49.49	73.29	77.49	79.33	75.65	66.98	75.84	94.31
Inventory	2.33B	3.04B	2.89B	3.19B	4.02B	8.98B	4.7B	5.42B	5.29B	6.56B
Days Inventory Outstanding	206.47	256.55	213.71	236.83	277.18	263.63	138.42	239.45	189.1	225.08
Other Current Assets	2.31B	1.68B	3.08B	392M	142M	1.22B	1.13B	3.75B	2.04B	1.25B
Total Non-Current Assets+	49.26B	50.2B	45.06B	45.81B	47.19B	79.12B	73.89B	76.06B	78.21B	85.35B
Property, Plant & Equipment	6.85B	7.62B	7.42B	8.34B	8.92B	10.17B	9.45B	10.5B	11.65B	14.7B
Fixed Asset Turnover	3.36x	2.95x	2.98x	2.93x	2.98x	3.68x	4.69x	4.36x	4.64x	4.00x
Goodwill	11.66B	11.82B	11.71B	11.67B	11.85B	20B	19.82B	20.05B	21.02B	21.24B
Intangible Assets	27.59B	26.19B	21.96B	20.83B	20.95B	42.39B	39.31B	38.09B	37.18B	37.85B
Long-Term Investments	-58M	-194M	113M	0	0	0	0	1.78B	0	2.52B
Other Non-Current Assets	2.13B	2.58B	1.48B	2.26B	2.04B	2.23B	2.05B	5.65B	3.01B	9.04B
Total Assets+	62.53B	63.35B	60.65B	61.38B	66.73B	105.36B	96.48B	101.12B	104.03B	114.07B
Asset Turnover	0.37x	0.35x	0.36x	0.40x	0.40x	0.36x	0.46x	0.45x	0.52x	0.51x
Asset Growth %	4%	1.32%	-4.27%	1.2%	8.72%	57.9%	-8.43%	4.81%	2.88%	9.65%
Total Current Liabilities+	15.26B	16.38B	16.29B	18.12B	20.31B	22.59B	26.29B	30.54B	27.87B	30.62B
Accounts Payable	1.68B	2.29B	1.72B	1.77B	2.35B	2.82B	2.55B	3.27B	3.64B	25.28B
Days Payables Outstanding	148.62	193.15	127.19	131.58	161.87	82.88	75.11	144.23	130.17	867.79
Short-Term Debt	2.24B	2.27B	1.78B	1.82B	2.19B	1.57B	5.22B	5.13B	2.16B	3.19B
Deferred Revenue (Current)	-5.88B	-6.44B	1.37B	0	0	0	0	0	0	0
Other Current Liabilities	4B	4.21B	3.73B	9.96B	12.27B	14.94B	15B	6.13B	17.31B	1.77B
Current Ratio	0.87x	0.80x	0.96x	0.86x	0.96x	1.16x	0.86x	0.82x	0.93x	0.94x
Quick Ratio	0.72x	0.62x	0.78x	0.68x	0.76x	0.76x	0.68x	0.64x	0.74x	0.72x
Cash Conversion Cycle	98.84	108.92	136	178.54	192.8	260.08	138.95	162.21	134.77	-548.4
Total Non-Current Liabilities+	30.6B	30.33B	30.32B	28.66B	30.78B	43.48B	33.13B	31.41B	35.3B	34.74B
Long-Term Debt	16.51B	17.39B	19.2B	15.73B	17.5B	28.13B	22.96B	22.36B	26.51B	24.71B
Capital Lease Obligations	6M	0	0	487M	489M	754M	725M	857M	1.11B	1.42B
Deferred Tax Liabilities	3.96B	4B	3.29B	2.49B	2.92B	6.21B	2.94B	31M	3.31B	3.51B
Other Non-Current Liabilities	14.08B	12.94B	11.11B	9.91B	9.83B	8.36B	6.48B	8.15B	4.37B	3.69B
Total Liabilities	45.86B	46.71B	46.61B	46.78B	51.09B	66.08B	59.42B	61.95B	63.16B	65.36B
Total Debt+	16.81B	17.81B	19.11B	18.23B	20.38B	30.69B	29.14B	28.62B	30.11B	29.7B
Net Debt	11.79B	14.48B	14.28B	12.86B	12.55B	24.36B	22.98B	22.78B	24.63B	23.99B
Debt / Equity	1.01x	1.07x	1.36x	1.25x	1.30x	0.78x	0.79x	0.73x	0.74x	0.61x
Debt / EBITDA	2.32x	2.65x	2.68x	2.73x	2.53x	5.95x	3.23x	2.18x	2.00x	1.53x
Net Debt / EBITDA	1.62x	2.16x	2.00x	1.92x	1.56x	4.72x	2.55x	1.74x	1.63x	1.23x
Interest Coverage	3.59x	2.70x	2.48x	2.09x	4.06x	0.83x	2.82x	5.16x	5.95x	8.11x
Total Equity+	16.67B	16.64B	14.04B	14.6B	15.64B	39.29B	37.06B	39.17B	40.87B	48.72B
Equity Growth %	-9.94%	-0.16%	-15.61%	3.93%	7.14%	151.23%	-5.67%	5.69%	4.35%	19.2%
Book Value per Share	6.58	6.57	5.54	5.61	5.96	13.77	11.88	12.54	13.07	15.60
Total Shareholders' Equity	14.85B	14.96B	12.47B	13.13B	15.62B	39.27B	37.04B	39.14B	40.79B	48.67B
Common Stock	316M	317M	317M	328M	328M	387M	387M	388M	388M	388M
Retained Earnings	8.14B	8.22B	5.68B	2.81B	5.3B	1.71B	-574M	4.52B	3.16B	10.97B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	99M	1.01B	34M	0	0	0	0	0	0	2.04B
Minority Interest	1.81B	1.68B	1.58B	1.47B	16M	19M	21M	23M	85M	52M

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	4.14B	3.58B	2.62B	2.97B	4.8B	5.96B	9.81B	10.35B	11.86B	15.19B
Operating CF Margin %	18.02%	15.93%	11.85%	12.18%	18.03%	15.94%	22.11%	22.58%	21.94%	25.86%
Operating CF Growth %	24.7%	-13.68%	-26.83%	13.41%	61.64%	24.26%	64.48%	5.48%	14.65%	28.08%
Net Income	3.55B	2.23B	1.99B	1.55B	3.92B	-265M	2.5B	6.9B	8.69B	10.22B
Depreciation & Amortization	2.36B	3.04B	3.75B	3.76B	3.15B	6.53B	5.48B	4.93B	5.07B	5.73B
Stock-Based Compensation	0	0	0	259M	277M	615M	619M	579M	0	0
Deferred Taxes	0	0	0	-259M	-277M	-615M	-619M	0	0	0
Other Non-Cash Items	-2.69B	-1.64B	-2.49B	-2B	-2.63B	-2.32B	-1.93B	-2.37B	-1B	395.79M
Working Capital Changes	926M	-50M	-639M	-346M	361M	2.02B	3.76B	300M	-893M	-1.16B
Change in Receivables	1.61B	83M	-523M	-898M	-739M	-961M	-1.35B	-1.43B	-1.62B	0
Change in Inventory	-343M	-548M	-13M	-316M	-621M	1.58B	3.94B	-669M	-131M	0
Change in Payables	0	0	0	898M	739M	961M	1.35B	1.43B	0	0
Cash from Investing+	-3.97B	-2.33B	963M	-657M	-285M	-11.06B	-2.96B	-4.06B	-7.98B	-7.25B
Capital Expenditures	-2.31B	-1.62B	-1.37B	-2.46B	-2.61B	-2.2B	-2.57B	-1.36B	-1.92B	-2.81B
CapEx % of Revenue	10.06%	7.21%	6.21%	10.09%	9.79%	5.88%	5.8%	2.97%	3.56%	4.78%
Acquisitions	-2.9B	-1.96B	-536M	-783M	-830M	-9.43B	-1.06B	-1.18B	-3.93B	-1.23B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.64B	1.62B	2.54B	2.39B	1.14B	654M	789M	-1.52B	-2.14B	-3.21B
Cash from Financing+	-1.32B	-2.94B	-2.04B	-1.76B	-2.2B	3.65B	-6.82B	-6.57B	-4B	-7.71B
Debt Issued (Net)	2.48B	224M	1.47B	-1.19B	1.65B	7.89B	-1.2B	-965M	1.81B	-2.39B
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	-1000K	-1000K
Dividends Paid	-3.56B	-3.52B	-3.48B	-3.59B	-3.57B	-3.86B	-4.36B	-4.48B	-4.63B	-5.08B
Share Repurchases	0	0	0	0	0	0	0	0	0	-719.66M
Other Financing	-285M	316M	-33M	3.01B	-308M	-418M	-1.29B	-1.15B	-1.13B	434.54M
Net Change in Cash	-1.13B	-1.75B	1.5B	552M	2.32B	-1.51B	-55M	-346M	-208M	237.82M
Free Cash Flow+	1.83B	1.96B	1.25B	509M	2.19B	3.76B	7.24B	6.57B	7.28B	11.77B
FCF Margin %	7.96%	8.72%	5.65%	2.09%	8.24%	10.06%	16.32%	14.34%	13.45%	20.03%
FCF Growth %	241.6%	6.94%	-36.31%	-59.18%	330.84%	71.59%	92.32%	-9.26%	10.78%	61.72%
FCF per Share	0.72	0.77	0.49	0.20	0.84	1.32	2.32	2.10	2.33	3.77
FCF Conversion (FCF/Net Income)	1.18x	1.19x	1.21x	2.22x	1.50x	53.24x	2.98x	1.74x	1.69x	1.48x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	19.89%	18.02%	14.05%	9.32%	21.14%	0.41%	8.61%	15.63%	17.58%	22.89%
Return on Invested Capital (ROIC)	13.18%	9.26%	8.55%	7.86%	13.92%	1.72%	4.56%	10.07%	11.77%	14.92%
Gross Margin	82.06%	80.78%	77.66%	79.82%	80.09%	66.76%	72.06%	81.95%	81.12%	81.9%
Net Margin	15.21%	13.36%	9.76%	5.47%	12.01%	0.3%	7.41%	13%	13.01%	17.46%
Debt / Equity	1.01x	1.07x	1.36x	1.25x	1.30x	0.78x	0.79x	0.73x	0.74x	0.61x
Interest Coverage	3.59x	2.70x	2.48x	2.09x	4.06x	0.83x	2.82x	5.16x	5.95x	8.11x
FCF Conversion	1.18x	1.19x	1.21x	2.22x	1.50x	53.24x	2.98x	1.74x	1.69x	1.48x
Revenue Growth	-6.9%	-2.33%	-1.67%	10.38%	9.16%	40.58%	18.53%	3.29%	18.04%	8.63%

AstraZeneca PLC (AZN) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare AZN vs Peers

vs LLY

vs JNJ

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

AstraZeneca PLC (AZN) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare AZN vs Peers

vs LLY

vs JNJ

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios